CT
Cameron Turtle (Chief Executive Officer) filed 11 Form 4 reports in the trailing twelve months (0 purchases, 11 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $1.4M of SYRE (14,184 sh across 3 lots, as filed), executed Aug 3. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
11
0 buys · 11 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$9.9M
shares × price, as filed
Last traded
Oct 1
Filed Oct 2
Median ADV $134.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $10.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
11 filings
Sector per market data · by filing · past 12 months
Most traded names
SYRERecent filings
SYRESALE
Spyre Therapeutics, Inc.
View filing →
$462K14,043 sh × $32.87
Exec Feb 2
Filed Feb 4 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $387K
12,709 sh × $30.47
Exec Jan 2
Filed Jan 6 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $435K
15,000 sh across 2 lots
Exec Dec 1 2025
Filed Dec 3 2025 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.0M
45,000 sh across 2 lots
Exec Nov 3 2025
Filed Nov 5 2025 · 5:30 PM ET